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cling types (positive, intermediate and negative) was also different in lesions with and 
wthout plaque rupture. 
Conclusion: In the femoro-popliteal circulation, the appearance of plaque rupture is 
common (43%) and is highly associated wth positive remodeling. 
2:15 pm. 
857-2 Hospital Volume and Mortality in Acute Aortic 
Dissection: Does Low Volume Predict Worse Outcome? 
Salil J. Patel, Rajendra H. Mehta, Linda Pape, Stuart Hutchinson, Dean E. Smith, Jeanna 
V. Cooper, Pat O’Gara, Toru Suzuki, Eric M. Isselbacher, Christoph A. Nienaber, Kim A. 
Eagle, University of Michigan, Ann Arbor, MI 
Background: Acute Aortic Dissection (AAD) is associated with a very high mortality. 
Studies have shown an increased mortality at low volume centers in coronary artery 
bypass and/or valve surgery. However, to our knowledge, no studies have assessed this 
relation in AAD. To characterize whether hospital volume correlates with mortality, we 
examined outcomes data in a large cohori of patients with AAD. 
Methods: We evaluated 962 patients enrolled in the International Registry of Aortic Dis- 
section (IRAD) between l/1996 and 10/2001. Data from 15 centers in 7 countries were 
included. Linear regression analysis was performed correlating mortality and annual hos- 
pital volume. Centers were grouped and analyzed into teriiles based on AAD’volume. 
Data between low and higher volume centers was compared using a Chi-square test. 
Further adjustment for morbidity was made by means of multivariate prediction models 
for predicted death both for proximal and distal AAD, creating an overall observed versus 
expected mortality risk for each hospital. 
Results: The number of AAD cases per hospital per year ranged from 4 to 34. Overall 
hospital mortality for AAD was 25%. Mortality rates for all AAD were not significantly dif- 
ferent between lowest volume and higher volume hospitals (p=O.27). Similarly, there 
were no significant differences in death between low and high volume centers for Type A 
dissection or Type A dissections managed surgically. While there was a trend for lower 
mortality in Type B dissection in higher volume centers (p=O.O45), the confidence limits 
surrounding the point estimate were wide. 
Conclusions: AAD continues to be associated with high in-hospital mortality rates. Our 
data, reflecting cases reported over recent years, did not show a convincing difference 
between volume and outcome for AAD, despite a large population of patients collected 
by multiple centers. Risk adjustment indicated that lower volume centers did not perform 
more poorly than higher volume institutions. It may be that volume of overall heart sur- 
gery, or perhaps aortic. aortic valve, or a combination of surgical procedures proves to be 
more improtant in determining mortality in AAD, not simply the number of AAD alone. 
2:30 p.m. 
857-3 The Effects of Exercise on Lower Extremity Functioning 
in Peripheral Arterial Disease Patients Without 
Intermittent Claudication: A Randomized Controlled 
Clinical Trial 
Mary M. McDermott Susan D. Tiukinhoy, Ty Gluckman, Shay Unterreiner, William H. 
Pearce, Michael H. Criqui, Kiang Liu, Jack M. Guralnik, Philip Greenland. Northwestern 
University Feinberg School of Medicine, Chicago, IL 
BACKGROUND: Most patients with lower extremity peripheral arlerial disease (PAD) do 
not have classical symptoms of intermlttent claudication (IC). We hypothesized that 
supervised exercise training would improve leg functioning in patients with PAD who do 
not have IC. METHODS: PAD subjects were identified from a non-invasive vascular lab- 
oratory at an academic medical center. Those without IC were included. Subjects were 
randomly assigned to a supervised treadmill exercise intervention vs. usual care. Exer- 
cise occurred 3 times weekly for 12 weeks for up to 60 minutes each session. The six- 
minute walk test was our primary outcome. We also measured fastest pace walkmg 
speed over 4 meters. We used intentlon to treat analyses. Of 35 enrolled, 26 completed 
baseline and follow-up testing. Of these, 54% had no exertional leg symptoms and 46% 
had exertional lea svmotoms other than IC. The table shows chanaes between baseline I , 
and follow-up. The Intervention group had a significant increase in B-minute walk pedor- 
mance between baseline and follow-uo fo=O.O2). CONCLUSION: Walkino endurance 
improved after a supervised exercise program in PAD patients without IC. If these find- 
ings are confirmed in a larger cohort, exercise may prove to have important effects on 
functional performance in PAD patients without IC. 
Changes in Lower Extremity Functianmg m Response lo Exercise 
Exercise Group (n=l6) Control group @IO) P Value 
6-minute walk (feet) 132.0 (124) 46.2 (216) 0.265 
Fast 4-meter walk (m/se@ 0.003 (0.16) -0.053 (0.14) 0.402 
2:45 p.m. 
857-4 Effects of Avasimibe in Claudicants With Peripheral 
Arterial Disease 
Willlam R. Hiatt, Ellen Klepack, Mark Nehler, James Imus, Judith Regensteiner, Michael 
Criqui, University of Colorado Health Sciences Center, Denver, CO, Pfizer Global 
Research and Development, Ann Arbor, Ml 
Background: Avasimibe. an Inhibitor of acyl coenzyme A-cholesterol acyltransferase 
(ACAT), was assessed for symptomatic improvement in moderate to severe claudication. 
Methods: Patients with chronic, stable, claudicatlon symptoms secondary to PAD 
(ankle-brachial index s 0.90 at rest with a 20% reduction post-exercise) were enrolled. 
Primary endpoint, change from baseline in absolute claudication distance (ACD) com- 
pared to placebo after 52 weeks of treatment of avasimlbe 50 mg, 250 mg, or 750 mg 
daily using a graded treadmill protocol (2 mph, 2% grade every 2 minutes). 
Results: TreadmIll results are shown in the table. Avasimibe 50 mg, although not statisti- 
cally significant after adjusting for multiple comparisons, demonstrated the greatest 
improvement in ACD compared to placebo (difference = 0.76 min, p=O.O27). This finding 
was supported by change in initial claudicatlon distance (ICD) (difference = 0.5 min, 
p=O.O26) and walking distance as measured by the Walking Impairment Questionnaire 
(WIQ) (difference = 5.5%, p=O.O56). 
Conclusion: The observed increase in ACD at the 50 mg dose, although not statlstically 
significant, may suggest a symptomatic benefit with chronic oral avasimibe in claudica- 
tion. 
Least-Squares Mean Change in Time to ACD From Baseline at Week 52, Mean (SE) 
Time to ACD (minutes) Placebo Avasimibe 
50 mg 250 mg 750 mg 
N 92 90 101 90 
Change’ 0.66 (0.26) 1.42 (0.26)’ 0.96 (0.25) 0.63 (0.26) 
N=number of patients 
’ ANCOVA model 
* P=O.O27 (P<O.O245 required for statistical significance) 
3:oo p.m. 
857-5 Cilostazol in Raynaud s Disease: A Double-Blind 
Placebo Controlled Clinical Trial 
San~av Rawao~alan, Dana Pfenninger, Christine Kehrer, Emily Somers, Anjan 
Chakraborti, William J. McCune, Debabrata Mukherjee, Robert D Brook, Mariana 
Kaplan, Uwersity of Michigan, Ann Arbor, Ml 
Background: Raynaud’s syndrome (RS) is characterized by recurrent episodes of 
vasospasm occuring in isolation (primary l.RS) or in association with rheumatologic 
states (secondary, 2.RS). We investigated the effect of the phosphodiesterase Ill inhibl- 
tor cllostazol I” this disorder. 
Methods: Subjects with moderate-severe RS were stratified by diagnosis (1 or 2.RS) 
and randomized to receive placebo or cilostazol 100 mglday bid for 6 weeks in a double- 
blind manner. Brachial artery vasoreactivity to assess conduit vessel function, laser Dop- 
pler fluxmetry to assess microvascular flow, and cold pressor testing (CPT) were per- 
formed at study entry and exit. Symptoms were assessed throughout the B-week 
duration using validated attack scores. 
Results: A total of 19 patients with 1 .RS and 21 patients with 2.RS matched for age, vas- 
cular risk factors, and symptom severity completed the study. Cilostazol, but not placebo, 
resulted in an increase in brachial artery diameter at 6 weeks, with a 16% and 17% 
increase in 1 .RS and 2.RS, respectively (P co.05 for both). There was no change in 
median flow-mediated dilation (FMD) (4.06 [25!“-7ti” percentile, 2.5-6.11 to -0.77 l-2.42. 
3.451) in 1 ii or Pii RS (2.23 [0.05 to 6.271 to 2.95 [1.69 to 7.41). Nitroglycerin-mediated 
dilation, microvascular flow indices, and symptom severity were unchanged in both 
cohorts. Cilostazol in l.RS, but not in 2.RS, resulted in a positive change in the slope of 
brachial responsiveness to CPT, which translated to an increase of 0.32 mmlmin com- 
pared with placebo (P = 0.002). Cilostazol treatment remained significantly associated 
with increased brachial artery diameter when controlled for body mass index, age, cho- 
lesterol, triglycerides, cholesterol/high-density lipoprotein ratio, and systolic blood pres- 
sure (P= 0.018). 
Conclusion: Cilostazol increases conduit vessel diameter in RS. There was a favorable 
Impact on conduit vessel responsiveness to cold in 1 .RS without impacting microvascular 
flow or symptoms at 6 weeks. A longer duration of treatment or higher doses may be 
required to see a benefit in these parameters in RS. These results provide Important 
Insights for designing future pharmacotherapeutic interventions in RS. 
3:15 p.m. 
857-6 A Prospective Case-Control Study of Tobacco 
Dependence in Thromboangiitis Obliterans (Buerger s 
Disease) 
Leslie T. Cooper, Stavonnie S. Henderson, Kenneth P. Offord. Tak Sun Tse, David R. 
Holmes, Richard D. Hurt, Mayo Clinic and Foundation, Rochester, MN 
Background: Thromboangiitis Obliterans (TAO) is often cited as an extreme phenotype of 
vasculopathy and tobacco dependence. Although tobacco exposure IS essential to pro- 
gression of arterial ischemia in TAO, expert opinion differs regarding the degree of 
tobacco dependence in this population. We designed a prospective, case-control study 
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to test the hypothesis that subjects with TAO have a greater degree of tobacco depen- 
dence than do control subjects with coronary atherosclerosis (CAD). 
Methods: Subjects with TAO (n = 218, confirmed by angiography, biopsy, or noninvasive 
arterial testing) or CAD (n=343, diagnosed by coronary angiography) were mailed a stan- 
dardized questionnaire regarding tobacco use, to which 103 and 273 responded, raspec- 
tively. Degree of tobacco dependence in each group was ascertained by several 
methods, including the Fagerstrtim Test for Nicotine Dependence Questionnaire. 
Resuks: The TAO group was younger at Index date (year of first diagnosis for TAO 
patients, year of PTCA for CAD patients) (TAO 37.6e9.0 vs CAD 43.3+4.9 yrs, P<.OOOl), 
but the groups did not differ in age at first tobacco exposure (TAO 16.7k3.1 vs CAD 
17.3k4.2 yrs, p=.67), current tobacco use at time of survey (TAO 54% vs CAD 46%, 
p=.17). or Fagerstrbm score (TAO 4.7t2.3 vs CAD 5.1~2.3, p=.24). Kaplan Meier curves 
showed no significant difference in time lo stopping tobacco use after first diagnosis 
(p=.798). TAO subjects smoked fewer cigarettes per day than CAD subjects (TAO 
22.3*10.7 vs CAD 27.7k15.3 cigarettes/day, p=.OO3). However, among current smokers 
(n=l53). the groups did not seem lo differ in number of cigarettes/day (19.6+7.9 vs. 
22.5+11 .l, p=.20). Individuals in the TAO group appeared to be more likely to have made 
a serious attempt to quit smoking than those in the CAD group (TAO 97%% vs CAD 
90%, p=O.O5). 
Conclusions: In contrast to case reports of extreme tobacco dependence in the TAO pop- 
ulation, the degree of tobacco dependence in subjects with TAO is similar to matched 
subjects with CAD. 
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1200-l 34 Low Bone Mineral Density Predicts Significant 
Coronary Artery Disease at Cardiac Catheterization 
Hillarv H. Traq Christine Z. Dickmson, Judith A. Boura, William W. ONeill, Pamela A. 
Marcovitz, William Beaumont Hospital, Royal Oak, MI 
Background: Osteoporosis and coronary disease (CAD) share several risk factors (age, 
diabetes, hyperlenslon [HTN], and smoking) and may be related. The purpose of this 
study is lo investigate whether osteoporosis is predictive of significant CAD compared 
with traditional risk factors. 
Methods: Dual energy x-rays absorp~iometry (DEXA) scan and cardiac cathererization 
were performed on 209 patients (163 females, 26 males) between l/2000 and 712002. 
DEXA scans were classified into 3 groups: normal, osteopenia, and osteoporosis based 
on World Health Organization criteria. Angiograms were classified as having significant 
CAD if 2 50% luminal stenosis was noted in a major coronary artery. Clinical variables 
(age, HTN, diabetes, smoking, family history of CAD, hyperlipidemia) were examined. 
Results: 117 patients had significant CAD. Patients with and without CAD were similar 
clinically and demographically. Unlvariate predictors of CAD ware osteoporosis, diabe- 
tes, hypertension, and family history of premature CAD (table). On multivariate analysts, 
odds ratio (OR) for CAD was highest for osteoporosis: O&5.0 (95% confidence interval, 
2.25-l 1 .l [PC O.OOOl]). 
Conclusion: The presence of osteoporosis predicts significant coronary stenosis with 
higher odds ratio than traditional risk factors. Our study is the flrsst to report an increase in 
documented CAD in patlents with osteoporosis. 
Variable Odds ratio 95% confidence interval P- value 
Osteoporosis 5 2.25 - 11.1 co.ooo1 
Hypertension 2.37 1.04 - 5.4 0.041 
Family history of premature CAD 2.79 1.26-6.18 0.012 
Diabetes mellitus 3.3 1.6 6.79 0.0012 
1200-135 Rheumatoid Arthritis Is Not Associated With Myocardial 
Infarction After Controlling for Other Risk Factors 
Jefferson T. Baer, Jesse A. Berlin, Daniel A. Albert, Stephen E. Kimmel, Universtty of 
Pennsylvania, Philadelphia, PA 
Background: Previous studies have suggested that patients with rheumatoid arthritis 
(RA) have an increased rate of cardiovascular death and myocardial infarction (Ml) com- 
pared to Ihe general population. However, the majority of these studies failed to control 
for known cardiac nsk factors, some of which appear to be more common in patients with 
RA. 
Methods: A case-control study of first MI. ages 40 through 75, was conducted among 36 
hospitals in a B-county area during a 3.year period. Cases were patients hospitalized 
with a first nonfatal MI, and controls ware randomly selected from the same geographic 
area. Self-report of physician diagnosed RA was collected via telephone Interviews, 
along with detailed information regardmg cardiac risk factors and current medications 
using state-of-the-art methods. Multivariable logistic regression was used to adjust for 
age, sex, race, hormone replacement therapy, body mass index (BMI), cigarette smok- 
ing, insurance, exercise, income, education, history of coronary disease, family history, 
hypertension (HTN), diabetes mellitus (DM), hyperlipidemia, nonsteroidal anti-inflamma- 
tory drug use, aspirin use, disease-modifying anti-rheumatic drug use, and number of 
doctor visits. 
Results: 1078 cases (4.74% with RA) and 4255 controls (3.62% with RA) were inter- 
wewed. There was an increased risk of myocardial mfarction (MI) in patients with RA in 
the unadjusted model (OR 1.42, 95% Cl: 1.02-l .97). However, after adjusting for con- 
founding, there was no increased risk from RA (OR 0.86, 95% Cl: 0.58-1.29). The vari- 
ables responsible for confounding were age, HTN, DM, BMI, history of coronary disease. 
education and number of doctor visits. There were no subgroups at mcreased risk of Ml 
from RA. 
Conclusions: Previous studies showing an increased risk of cardiovascular death III 
patients with RA did not control for known cardiac risk factors. The current study showed 
an increased risk of MI in patients with RA that was solely explained by RA patients’ 
greater prevalence of several rksk factors. Physicians should aggressively screen for and 
modify common cardiac risk factors in patients with RA. 
1200-l 36 Green Tea Derived Polyphenol Antioxidant, EGCG, 
Differentially Modulates Developing Compared to 
Mature Atherosclerotic Lesions in Apo E -/- Mice 
Stephanie M. Babbidqg, Xiaonmg Zhao. Ramprasad Dandillaya, Juliana Yano, Paul C. 
Dimayuga, Bojan Cercek, Prediman K. Shah, Kuang-Yuh Chyu, Cedars-Sinai Medical 
Center, Los Angeles, CA 
Background: Atherosclerosis starts at a young age, but therapy IS generally begun 
when the disease is well established. Therapy such as green tea derived polyphenol anti- 
oxidant epigallocatechm gallate (EGCG) may be more effective when applied during the 
developing rather than established phase of atherosclerosis. 
Hypothesis: Developing atherosclerotic lesions are differentially modulated by anti-oxi- 
dant therapy compared lo mature atherosclerotic lesions. 
Methods: Newly developing atherosclerotic lesions were Induced by placing a carotid 
cuff in apoE (-i-) hypercholesterolemic mice at 26 weeks of age. EGCG (10 mgikg, n=7) 
or PBS (n=7) was injected i.p. daily. Sections of cuffed arteries ware stained for PCNA. 
H&E and oil-red-O. Aortic sinus plaques from the same animals were stained for collagen 
content and macrophage. Plasma cholesterol and antioxidant potential were also mea- 
sured. 
Results: Newly developed lipid-rich atheroma in the carotid artery were smaller in the 
EGCG group compared to the PBS group 21 days after cuffing. EGCG treatment 
reduced medial PCNA expression 3 days after cuffing (Table). Mature aortic sinus 
plaques were not affected by EGCG (Table). BW and cholesterol levels were compara- 
ble in both groups. EGCG level 1 hour after injection was 138 * 44 ng/mL (n=5). 
Conclusion: Our data suggest that antioxidant therapy inhibits the formation of develop- 
ing, but not mature plaques. This observation implies timing of ant&dam therapy may 
be critical for antlatherogenic effect. 
Gr Carotid Carotid Sinus Sinus Plaque Sinus Plasma 
o” PCNA plaque Size Plaque Macrophage Plaque antioxidant 
P (day 3) (mm2, Size (mn?) (%) Collagen level# 
(%) 
E 7.4i6.2* 0.014iO.008 0.899&0.16 14.6k2.8 4O.lk6.6 1.147 * 
G (37 * 0.579* 
C sections) 
G 
P 11.9i10.7 0.031~0.013 0.851*0.16 17.2+4.6 
B (25 
S sections) 
42.5k3.2 0.262 f 
0.290 
meankstd; *p < 0.05 vs. PBS group; #mM uric acid equivalents 
1200-137 Downregulation of Microfilament Expression in 
Atherosclerotic Plaque Is Mediated bv Oxidized Low- 
Density Lipoprotein’ 
Koichi Ono Tao Peng, Jie Du, Yusuke Higashi. Yoshifumi Okura, Hiroyuki Itabe, Arkady -I 
Goubine. PatrIce Delafontaine, The University of Kansas Medical Center, Kansas City, 
KS 
The cellular microfilament system is a highly dynamic network comprised of multiple pro- 
teins that are essential for cell motility, contraction, cell-cell and cell-substrate interac- 
tions, signalmg pathways, gene expression and cell differentiation. To examine the 
regulation of Vascular Smooth Muscle Cell (VSMC) mvxofilaments in atherosclerotic 
plaque development we performed immunostaining fora-, p-actin and wmentm in human 
femoral and carotid atherosclerotic plaques (n=20). There was a marked reduction in a- 
actin and vimentin expression in VSMC in advanced plaque. To identify stimuli that 
downregulate microfilament components in plaque, we incubated human VSMC with O- 
100 uglml Oxidized LDL (OxLDL), an important proatherogenic molecule, or o-100 us/ml 
native LDL (nLDL) and measured cytoskeletal protein expression by western immunob- 
lotting. OxLDL, but not nLDL, dose dependently reduceda-actin and vimentin expression 
(21 r 5%, n=8. pc.05, and 52 * 6%. n=19. pcO.0001, respectively, with 100 ug/ml 
OxLDL) and non-significantly increased p-&in expresston. To determine intracellular 
signaling pathways mediating OxLDL effects on microfilaments we studied the effect of 
candidate proteins implicated in OxLDL stgnalmg. OxLDL components are high-affinity 
liaands for the PPARvnuclear recer&r. but the effect of OxLDL was not blocked bv the 
P>ARy inhibitor, PGF; a, 200 nM, and the synthetic PPARy lkgand ciglitazone (0.1O’uM) 
did not reaulate vimentm or a-actin exmesslon. Furthermore. inhibition of the ~38 MAPK 
pathway (88203580, 10 uM) did not modify OxLDL effects, Indicating that the ability of 
OxLDL to regulate vlmentinla-actln was not mediated via a p38 MAPK dependent path- 
way. In conclusion: 
